1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22446
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLivadas, S.en
dc.contributor.authorHadjidakis, D. J.en
dc.contributor.authorArgyropoulou, M. I.en
dc.contributor.authorStamatelatou, M.en
dc.contributor.authorKelekis, D.en
dc.contributor.authorRaptis, S. A.en
dc.date.accessioned2015-11-24T19:24:16Z-
dc.date.available2015-11-24T19:24:16Z-
dc.identifier.issn1109-3099-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22446-
dc.rightsDefault Licence-
dc.subjectAcromegaly/drug therapyen
dc.subjectAdenoma/drug therapy/pathology/*secretionen
dc.subjectAntineoplastic Agents/*administration & dosageen
dc.subjectFemaleen
dc.subjectHuman Growth Hormone/*secretionen
dc.subjectHumansen
dc.subjectMagnetic Resonance Imagingen
dc.subjectMiddle Ageden
dc.subject*Neoplasm Recurrence, Localen
dc.subjectPeptides, Cyclic/*administration & dosageen
dc.subjectPituitary Neoplasms/drug therapy/pathology/*secretionen
dc.subjectSomatostatin/administration & dosage/*analogs & derivativesen
dc.titleDisappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawalen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16728386-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2006-
heal.abstractAcromegaly is caused by excessive growth hormone secretion, usually from a pituitary adenoma. The use of somatostatin analogues as primary or adjunctive therapy has been widely applied in the management of acromegaly. We are aware of only three reported cases of complete shrinkage of a pituitary adenoma after long-term analogue administration. However in these cases, the reduction in the dimension of the adenoma was obtained with the everyday use of somatostatin analogues and not with the newer longer acting formulations. We report a patient in whom long term (62 months) lanreotide-L.A.R administration resulted in complete disappearance of a growth hormone secreting pituitary macroadenoma, followed by recurrence of the adenoma six months post therapy discontinuation.en
heal.journalNameHormones (Athens)en
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons